Anti-neuroinflammatory, protective effects of the synthetic microneurotrophin BNN-20 in the advanced dopaminergic neurodegeneration of "weaver" mice

Neuropharmacology. 2020 Mar 15:165:107919. doi: 10.1016/j.neuropharm.2019.107919. Epub 2019 Dec 23.

Abstract

BNN-20 is a synthetic microneurotrophin, long-term (P1-P21) administration of which exerts potent neuroprotective effect on the "weaver" mouse, a genetic model of progressive, nigrostriatal dopaminergic degeneration. The present study complements and expands our previous work, providing evidence that BNN-20 fully protects the dopaminergic neurons even when administration begins at a late stage of dopaminergic degeneration (>40%). Since neuroinflammation plays a critical role in Parkinson's disease, we investigated the possible anti-neuroinflammatory mechanisms underlying the pharmacological action of BNN-20. The latter was shown to be microglia-mediated, at least in part. Indeed, BNN-20 induced a partial, but significant, reversal of microglia hyperactivation, observed in the untreated "weaver" mouse. Furthermore, it induced a shift in microglia polarization towards the neuroprotective M2 phenotype, suggesting a possible beneficial shifting of microglia activity. This observation was further supported by morphometric measurements. Moreover, BDNF levels, which were severely reduced in the "weaver" mouse midbrain, were restored to normal even after short-term BNN-20 administration. Experiments in "weaver"/NGL (dual GFP/luciferase-NF-κВ reporter) mice using bioluminescence after a short BNN-20 treatment (P60-P74), have shown that the increase of BDNF production was specifically mediated through the TrkB-PI3K-Akt-NF-κB signaling pathway. Interestingly, long-term BNN-20 treatment (P14-P60) significantly increased dopamine levels in the "weaver" striatum, which seems to be associated with the improved motor activity observed in the treated mutant animals. In conclusion, our findings suggest that BNN-20 may serve as a lead molecule for new therapeutic compounds for Parkinson's disease, combining strong anti-neuroinflammatory and neuroprotective properties, leading to elevated dopamine levels and improved motor activity.

Keywords: BDNF production; Microglia-polarization; Microneurotrophin; Neuroprotection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / administration & dosage*
  • Brain-Derived Neurotrophic Factor / metabolism
  • Dehydroepiandrosterone / administration & dosage
  • Dehydroepiandrosterone / analogs & derivatives*
  • Disease Models, Animal
  • Dopaminergic Neurons / drug effects*
  • Dopaminergic Neurons / metabolism*
  • Encephalitis / complications
  • Encephalitis / metabolism*
  • Encephalitis / prevention & control
  • Female
  • Male
  • Membrane Glycoproteins / metabolism
  • Mice, Neurologic Mutants
  • Microglia / drug effects
  • Microglia / metabolism
  • Neuroprotective Agents / administration & dosage*
  • Parkinson Disease / complications
  • Parkinson Disease / metabolism*
  • Parkinson Disease / prevention & control
  • Pars Compacta / drug effects
  • Pars Compacta / metabolism
  • Protein-Tyrosine Kinases / metabolism
  • Tyrosine 3-Monooxygenase / metabolism

Substances

  • Anti-Inflammatory Agents
  • BNN20 compound
  • Bdnf protein, mouse
  • Brain-Derived Neurotrophic Factor
  • Membrane Glycoproteins
  • Neuroprotective Agents
  • Dehydroepiandrosterone
  • Tyrosine 3-Monooxygenase
  • Ntrk2 protein, mouse
  • Protein-Tyrosine Kinases